Abstract
The first prophylactic vaccine, Hecolin®, against hepatitis E virus (HEV) infection and the HEV associated disease was approved by China's State Food and Drug Administration (SFDA) in December 2011. Key milestones during the 14-year HEV vaccine development are summarized in this commentary. After years of innovative research the recombinant virus-like particle (VLP) based antigen with virion-like epitopes was successfully produced in E. coli production platform on a commercial scale. Safety and efficacy of this vaccine was demonstrated in a large scale phase III clinical trial.
Cite
CITATION STYLE
Wu, T., Li, S.-W., Zhang, J., Ng, M.-H., Xia, N.-S., & Zhao, Q. (2012). Hepatitis E vaccine development. Human Vaccines & Immunotherapeutics, 8(6), 823–827. https://doi.org/10.4161/hv.20042
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
